Company Performance - ADC Therapeutics SA (ADCT) has shown a year-to-date performance increase of approximately 69.9%, significantly outperforming the average gain of 3.1% in the Medical sector [4] - The Zacks Consensus Estimate for ADCT's full-year earnings has risen by 9.4% over the past three months, indicating a positive trend in analyst sentiment [3] Industry Comparison - ADC Therapeutics SA is part of the Medical - Biomedical and Genetics industry, which consists of 504 companies and currently ranks 83 in the Zacks Industry Rank. The average performance of this industry has seen a decline of 2.7% this year, highlighting ADCT's superior performance [5] - In contrast, Agios Pharmaceuticals, another stock in the Medical sector, has returned 99.5% year-to-date and belongs to the Medical - Products industry, which has gained 13.7% this year and ranks 68 [4][6] Zacks Rank - ADC Therapeutics SA holds a Zacks Rank of 2 (Buy), suggesting it is positioned to outperform the broader market in the near term [3]

2Q 2024 Earnings Call THERAPEUTICS Innovating Science. Inspiring Hope. August 6, 2024 Agenda | --- | --- | --- | --- | |-------|-------|--------------------------------------|------------------| | 01 | | Ameet Mallik Chief Executive Officer | Business Update | | 02 | | Pepe Carmona Chief Financial Officer | Financial Update | | 03 | Q&A | | | 2 Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us") for ...

Financial Data and Key Metrics Changes - For Q2 2024, ADC Therapeutics reported revenues of $17 million, a decrease from $17.8 million in Q1 2024 and $19.2 million in Q2 2023, with year-to-date revenues of $34.9 million compared to $38.2 million in the same period last year [7][18][19] - The net loss for Q2 2024 was $36.5 million or $0.38 per share, while the adjusted net loss was $24.4 million or $0.25 per share, reflecting a decrease in both reported and adjusted net loss compared to Q2 2023 due to lower operating expenses [20][21] Business Line Data and Key Metrics Changes - ZYNLONTA remains the primary focus, with net product revenues of $17 million for Q2 2024, down from $19.2 million in Q2 2023, attributed to lower sales volume and higher gross-to-net deductions [18][19] - The company achieved commercial profitability in 2024, with a disciplined capital allocation strategy leading to a 23% reduction in operating expenses year-over-year on a non-GAAP basis [11][19] Market Data and Key Metrics Changes - The competitive landscape for ZYNLONTA in the third-line plus DLBCL market remains challenging, with increased competition from bispecific therapies, yet the company has maintained its position as a treatment option [8][9] - The company is expanding its market presence by pursuing opportunities in earlier lines of DLBCL therapy and indolent lymphomas, which could significantly increase the commercial opportunity [11][14] Company Strategy and Development Direction - The company's strategy focuses on hematology and solid tumor pipelines, with ZYNLONTA as a key asset and ADCT-601 targeting AXL as the most advanced solid tumor asset [6][7] - ADC Therapeutics aims to expand ZYNLONTA's usage into second-line plus DLBCL and indolent lymphomas, with potential peak sales exceeding $500 million [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ZYNLONTA's role in the current treatment landscape, highlighting its clinical profile and the potential for further market penetration despite increasing competition [8][9] - The company anticipates significant milestones in the second half of 2024, including completion of enrollment in key trials and initial data from ongoing studies [21] Other Important Information - The company reported cash and cash equivalents of approximately $300 million as of June 30, 2024, providing a strong balance sheet to support its strategic initiatives [18] - ADC Therapeutics is exploring partnerships for its solid tumor programs and has selected one preclinical ADC candidate to advance towards IND, expected to be disclosed in 2025 [10][17] Q&A Session Summary Question: Regarding LOTIS-5 interim look, were there any other statistical considerations? - The independent data monitoring committee recommended continuing the trial without modifications after reviewing unblinded efficacy and safety data [24] Question: Can you provide more details on upcoming milestones? - Most data will be disclosed through corporate announcements, particularly for LOTIS-7 and AXL trials, with full data expected in the first half of next year [26] Question: Can you elaborate on the variability in ZYNLONTA orders? - Variability is attributed to the nature of orders from institutions and community physicians, with some months seeing significantly higher orders than others [29] Question: How do you expect Roche's STARGLO data to affect market dynamics? - The STARGLO data validates the efficacy of combinations with bispecifics, providing confidence in LOTIS-5 and LOTIS-7 trials [34][35] Question: Is there a possibility to include interim data into guidelines before full results? - It is possible, but would require presentation at a major medical congress and publication in a key journal [39]

Product Development and Pipeline - ADC Therapeutics aims to expand its ADC portfolio focusing on hematology and solid tumors, leveraging a validated technology platform and strategic partnerships [115]. - ZYNLONTA, the flagship product, received accelerated FDA approval for relapsed or refractory DLBCL, with ongoing international expansion efforts and clinical trials [116]. - In the LOTIS-7 trial, ZYNLONTA combined with bispecific antibodies showed promising anti-tumor activity with no dose-limiting toxicities observed in the dose escalation phase [119]. - Initial data from a Phase 2 trial of ZYNLONTA in relapsed/refractory MZL indicated a 86.7% complete response rate among evaluable patients, highlighting its potential in a high unmet need area [126]. - The solid tumor pipeline includes ADCs targeting NaPi2b and Claudin-6, currently in IND-enabling studies, with PSMA and ASCT2 candidates in drug selection stage expected to complete this year [129]. - The company is developing optimized ADCs targeting Claudin-6 and NaPi2b, with potential high impact in platinum-resistant ovarian cancer and non-small cell lung cancer [132]. - The company hosted a Research Investor Event to discuss its novel exatecan-based ADC platform, emphasizing its differentiated profile and therapeutic index [131]. Clinical Trials and Results - The LOTIS-7 trial is a global multicenter study evaluating ZYNLONTA in combination with bispecific antibodies, with ongoing enrollment in the dose expansion phase [122]. - As of April 2024, the LOTIS-7 trial reported that 88.8% of patients experienced Grade 3/4 adverse events, with manageable safety profiles observed [125]. - The company plans to pursue regulatory pathways for ZYNLONTA in MZL as trial results continue to be positive, aiming to address the high unmet medical need in this patient population [128]. Financial Performance - Product revenues, net, decreased to $17.0 million for the three months ended June 30, 2024, down $2.2 million or 11.3% from $19.2 million in the same period of 2023 [140]. - Total revenue, net, was $17.4 million for the three months ended June 30, 2024, a decrease of $1.9 million or 9.7% from $19.3 million in the same period of 2023 [138]. - License revenues and royalties increased significantly to $380 thousand for the three months ended June 30, 2024, compared to $86 thousand in the same period of 2023, representing a 341.9% increase [143]. - Net loss for the three months ended June 30, 2024, was $36.5 million, a decrease of $12.4 million or 25.3% from a net loss of $48.9 million in the same period of 2023 [138]. - Net loss per share, basic and diluted, improved to $(0.38) for the three months ended June 30, 2024, compared to $(0.60) in the same period of 2023, reflecting a 36.7% improvement [138]. - Total revenue decreased to $35.5 million for the six months ended June 30, 2024, down from $38.3 million in 2023, a decline of $2.8 million or 7.3% [172]. - Net loss for the six months ended June 30, 2024, was $83.2 million, compared to a net loss of $108.3 million in 2023, a reduction of $25.1 million or 23.2% [172]. - Product revenues, net, decreased to $34.9 million for the six months ended June 30, 2024, down from $38.2 million for the same period in 2023, representing an 8.6% decline [173]. Expenses and Cost Management - Research and development expenses decreased to $24.3 million for the three months ended June 30, 2024, down $7.0 million or 22.5% from $31.3 million in the same period of 2023 [148]. - Research and development expenses totaled $50.0 million for the six months ended June 30, 2024, a decrease of 28.2% from $69.7 million for the same period in 2023 [179]. - Selling and marketing expenses decreased to $10.7 million for the three months ended June 30, 2024, down from $14.5 million in 2023, a reduction of $3.8 million or 26.0% [161]. - General and administrative expenses were $10.2 million for the three months ended June 30, 2024, compared to $12.0 million in 2023, a decrease of $1.8 million or 14.7% [164]. - Research and development expenses for ZYNLONTA were $12.2 million for the three months ended June 30, 2024, down $4.4 million from $16.5 million in the same period of 2023 [149]. - Research and development expenses for ZYNLONTA were $27.1 million for the six months ended June 30, 2024, down from $35.8 million for the same period in 2023, a decrease of 24.0% [180]. - Selling and marketing expenses were $22.1 million for the six months ended June 30, 2024, down 25.9% from $29.8 million for the same period in 2023 [189]. - General and administrative expenses decreased to $22.3 million for the six months ended June 30, 2024, from $27.5 million for the same period in 2023, a reduction of 19.0% [192]. Cash Flow and Financing - The company completed an equity offering in May 2024, raising approximately $105.0 million in gross proceeds, with net proceeds of approximately $97.4 million after transaction costs [134]. - The company recorded a net cash used in operating activities of $76.9 million for the six months ended June 30, 2024, compared to $50.4 million for the same period in 2023, an increase of $26.6 million [206]. - Net cash provided by financing activities was $99.1 million for the six months ended June 30, 2024, primarily from the completion of the 2024 Equity Offering [208]. - The company had cash and cash equivalents of $300.1 million as of June 30, 2024, sufficient to fund operations for at least the next twelve months [201]. - The company recorded an income tax expense of $(0.4) million for the six months ended June 30, 2024, compared to a benefit of $4.0 million for the same period in 2023 [199]. - The company had an accumulated deficit of $1,418.6 million as of June 30, 2024, with operations historically funded through equity offerings and debt financings [202]. Interest Income and Expense - Interest income increased to $3.3 million for the three months ended June 30, 2024, up from $2.4 million in the same period of 2023, an increase of $0.9 million [165]. - Interest expense rose to $12.7 million for the three months ended June 30, 2024, compared to $10.3 million in 2023, an increase of $2.4 million or 23.0% [165]. - Interest income increased to $6.2 million for the six months ended June 30, 2024, up 36.4% from $4.5 million for the same period in 2023 [193]. - Interest expense rose to $25.2 million for the six months ended June 30, 2024, an increase of 22.2% from $20.6 million for the same period in 2023 [194].

Company Performance - ADC Therapeutics reported a quarterly loss of $0.38 per share, better than the Zacks Consensus Estimate of a loss of $0.44, and an improvement from a loss of $0.58 per share a year ago [1] - The company posted revenues of $17.41 million for the quarter, missing the Zacks Consensus Estimate by 8.63%, and down from $19.28 million year-over-year [1] - Over the last four quarters, ADC Therapeutics has surpassed consensus EPS estimates two times and topped revenue estimates just once [1] Stock Movement and Outlook - ADC Therapeutics shares have increased by approximately 72.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.7% [2] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [2][3] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $20.06 million, and for the current fiscal year, it is -$1.87 on revenues of $78.17 million [4] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - VistaGen Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.41 per share, reflecting a year-over-year change of +56.4%, with revenues expected to be $0.3 million, up 66.7% from the previous year [5]

[Executive Summary](index=1&type=section&id=Executive%20Summary) ADC Therapeutics reported its Q2 2024 results, highlighting that its key product, ZYNLONTA®, achieved commercial profitability in the first half of the year - **ZYNLONTA®** achieved commercial profitability in the first half of 2024[2](index=2&type=chunk)[3](index=3&type=chunk) - The company's cash runway has been extended into mid-2026 following a recent underwritten offering[2](index=2&type=chunk)[6](index=6&type=chunk) - Key clinical trial updates are expected by year-end 2024 for LOTIS-7 and in H1 2025 for mature data. Full enrollment for the LOTIS-5 trial is expected before year-end 2024[1](index=1&type=chunk) [Operational Updates and Pipeline Highlights](index=1&type=section&id=Operational%20Updates%20and%20Pipeline%20Highlights) The company reported ZYNLONTA® net sales of $17.0 million for Q2 2024, with demand affected by ordering variability, while key clinical programs are advancing [ZYNLONTA® Commercial Performance](index=1&type=section&id=ZYNLONTA%C2%AE%20Commercial%20Performance) ZYNLONTA® generated net product sales of $17.0 million in Q2 2024, representing a 5% decrease from the previous quarter, partly due to ordering variability ZYNLONTA® Net Sales | Metric | Q2 2024 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Net Sales | $17.0M | $17.8M | -5% | - Demand was impacted in part by variability in ordering patterns during the second quarter[3](index=3&type=chunk) [ZYNLONTA® Clinical Development](index=1&type=section&id=ZYNLONTA%C2%AE%20Clinical%20Development) Progress continues across ZYNLONTA's clinical development programs, with LOTIS-7 and LOTIS-5 trials on track for enrollment completion by year-end 2024 - LOTIS-7 (Phase 1b): Enrollment in the dose expansion part is progressing and expected to complete by year-end, with a safety and efficacy update anticipated by year-end 2024[3](index=3&type=chunk) - LOTIS-5 (Phase 3): An independent committee recommended the trial continue as planned. Full enrollment is expected before year-end 2024[4](index=4&type=chunk) - Investigator-initiated trial in MZL: Initial data from 15 evaluable patients showed **13 complete responses** and **1 partial response**[5](index=5&type=chunk) [Early-Stage Pipeline Development](index=3&type=section&id=Early-Stage%20Pipeline%20Development) The company's early-stage pipeline is advancing, with ADCT-601 Phase 1b trial enrolling patients and IND-enabling studies progressing for new ADC targets - ADCT-601 (targeting AXL): The Phase 1b trial continues enrollment, with an initial update from the trial expected in H2 2024[5](index=5&type=chunk) - Progress continues in IND-enabling studies for ADCs targeting PSMA, NaPi2b, and Claudin-6. The company expects to disclose one target to move toward IND in 2025[6](index=6&type=chunk) [Second Quarter and First Half 2024 Financial Results](index=3&type=section&id=Second%20Quarter%20and%20First%20Half%202024%20Financial%20Results) For Q2 2024, ADC Therapeutics reported total revenues of $17.4 million and a net loss of $36.5 million, an improvement from Q2 2023, with cash strengthened to $300.1 million [Financial Position](index=3&type=section&id=Financial%20Position) As of June 30, 2024, the company's cash and cash equivalents stood at $300.1 million, an increase from $278.6 million at the end of 2023, bolstered by a recent offering Cash and Cash Equivalents | Date | Amount (in millions) | | :--- | :--- | | June 30, 2024 | $300.1 | | Dec 31, 2023 | $278.6 | - A May 2024 underwritten offering resulted in net proceeds of approximately **$97.4 million**, extending the cash runway into mid-2026[6](index=6&type=chunk) [Statement of Operations Analysis](index=3&type=section&id=Statement%20of%20Operations%20Analysis) In Q2 2024, net product revenues decreased to $17.0 million, but operating expenses were significantly reduced, leading to an improved net loss of $36.5 million Q2 2024 vs. Q2 2023 Financial Performance (in millions) | Metric | Q2 2024 | Q2 2023 | | :--- | :--- | :--- | | Product Revenues, Net | $17.0 | $19.2 | | R&D Expense | $24.3 | $31.3 | | S&M Expense | $10.7 | $14.5 | | G&A Expense | $10.2 | $12.0 | | Net Loss | ($36.5) | ($48.9) | | Net Loss Per Share | ($0.38) | ($0.60) | - The decrease in operating expenses was driven by productivity initiatives, focused investment in prioritized programs, and lower marketing and personnel costs[7](index=7&type=chunk)[8](index=8&type=chunk) [Non-GAAP Financial Measures](index=4&type=section&id=Non-GAAP%20Financial%20Measures) On a non-GAAP basis, the adjusted net loss for Q2 2024 was $24.4 million, a favorable comparison to $32.1 million in Q2 2023, primarily due to lower operating expenses Q2 Adjusted Financials (Non-GAAP) | Metric | Q2 2024 | Q2 2023 | | :--- | :--- | :--- | | Adjusted Net Loss | ($24.4M) | ($32.1M) | | Adjusted Net Loss per Share | ($0.25) | ($0.39) | [Appendices](index=4&type=section&id=Appendices) This section includes supplementary information such as investor call details, company and product background, non-GAAP measure explanations, forward-looking statements, and detailed unaudited financial tables [Condensed Consolidated Statements of Operation](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operation) This unaudited statement details the company's revenues and expenses for the three and six months ended June 30, 2024, and 2023, showing a Q2 2024 net loss of $36.5 million Key Financial Data (Three Months Ended June 30, in thousands) | Description | 2024 | 2023 | | :--- | :--- | :--- | | Total revenue, net | $17,410 | $19,283 | | Total operating expense | ($46,451) | ($58,932) | | Loss from operations | ($29,041) | ($39,649) | | Net loss | ($36,544) | ($48,922) | [Condensed Consolidated Balance Sheet](index=9&type=section&id=Condensed%20Consolidated%20Balance%20Sheet) This unaudited statement presents the company's financial position as of June 30, 2024, compared to December 31, 2023, showing total assets of $371.8 million Key Balance Sheet Data (in thousands) | Description | June 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $300,119 | $278,598 | | Total assets | $371,779 | $354,782 | | Total liabilities | $503,449 | $503,031 | | Total shareholders' equity (deficit) | ($131,670) | ($148,249) | [Reconciliation of GAAP to Non-GAAP Measures](index=11&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) This section provides a detailed reconciliation of GAAP financial figures to non-GAAP adjusted figures, bridging the GAAP net loss of $36.5 million to an adjusted net loss of $24.4 million for Q2 2024 - The reconciliation bridges GAAP net loss to adjusted net loss by excluding non-cash items like share-based compensation and changes in fair value of warrants, as well as certain interest expenses[29](index=29&type=chunk)[30](index=30&type=chunk)[31](index=31&type=chunk) [About ZYNLONTA®](index=4&type=section&id=About%20ZYNLONTA%C2%AE) ZYNLONTA® is a CD19-directed antibody-drug conjugate (ADC) approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy - ZYNLONTA is a CD19-directed ADC designed to be internalized by CD19-expressing cells, where it releases a PBD payload to cause cell cycle arrest and death[12](index=12&type=chunk) - It is approved for r/r large B-cell lymphoma after two or more lines of systemic therapy under accelerated/conditional approval pathways[13](index=13&type=chunk) [About ADC Therapeutics](index=5&type=section&id=About%20ADC%20Therapeutics) ADC Therapeutics is a commercial-stage global company pioneering antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors, with its lead product ZYNLONTA® approved for diffuse large B-cell lymphoma - The company is a commercial-stage leader in the field of antibody-drug conjugates (ADCs)[15](index=15&type=chunk) - It is based in Lausanne, Switzerland, with operations in London and New Jersey[16](index=16&type=chunk) [Forward-Looking Statements](index=6&type=section&id=Forward-Looking%20Statements) This section serves as a legal disclaimer, cautioning that the press release contains forward-looking statements subject to significant risks and uncertainties, where actual results could differ materially from expectations - The document contains forward-looking statements that are not guarantees of future performance and are subject to risks and uncertainties[21](index=21&type=chunk) - Key risks include the ability to grow ZYNLONTA revenue, timing and results of clinical trials (LOTIS 5, LOTIS 7, ADCT 601), regulatory outcomes, and restrictions from indebtedness[21](index=21&type=chunk)

Core Viewpoint - ADC Therapeutics SA is set to report its financial results for Q2 2024 and provide operational updates during a conference call on August 6, 2024 [1] Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors through its proprietary ADC technology [2] - ADC Therapeutics' CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy, alongside multiple ADCs in clinical and preclinical development [2] Operational Details - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [3] - A live webcast of the upcoming conference call will be available on the ADC Therapeutics website, with an archived version accessible for 30 days post-call [1]

Company Overview - Myricx Bio is a UK biotech company focused on developing a novel class of payloads for antibody-drug conjugates (ADCs) based on inhibitors of N-Myristoyltransferases (NMT) for cancer treatment [7] - The company was founded by Prof. Ed Tate, Dr. Roberto Solari, and Dr. Andrew Bell, and has transitioned from a virtual company to a fully-fledged R&D company with its own laboratories and in-house R&D team [5][6] Funding and Investment - Myricx Bio has successfully closed a £90 million ($114 million) Series A financing round, co-led by Novo Holdings and Abingworth, with participation from British Patient Capital, Cancer Research Horizons, and Eli Lilly [1][2] - The funds will be utilized to expand Myricx's proprietary NMTi ADC payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept [2][3] Scientific Advancements - Myricx has demonstrated that its initial NMTi-ADCs achieve complete and durable tumor regressions at well-tolerated doses in multiple solid cancer models [3] - The NMTi-ADCs show potent bystander activity and deliver high efficacy in patient-derived xenograft (PDX) organoid models across a broad range of antigen expression levels [3] Management and Strategic Growth - The company is establishing laboratory operations in London's biotech hub and expanding its management and R&D teams [1][5] - New board members include Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth, indicating strong support from leading life science investors [1][2] Market Position and Future Outlook - Myricx aims to address serious unmet needs in oncology with its innovative NMTi payload chemistry platform, which has shown excellent preclinical efficacy and safety [2][7] - The company is well-positioned to leverage its NMTi-ADC platform and advance both its pipeline and strategic partnerships, aiming to become a significant player in the ADC space [5][6]

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the f ...

Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality. It comes down to the same theme. Good health is ultimately more important than any amount of money you can generate. Therefore, biotech stocks to buy offer a permanently relevant storyline. That's no ...